Marqeta Inc vs Tilray Brands Inc — how do they compare? Marqeta Inc trades at $17.21 (market cap $1.85B), while Tilray Brands Inc trades at $4.25 (market cap $524.07M). The key difference: Marqeta Inc is far larger — about 3.5× Tilray Brands Inc's market cap, and Marqeta Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| MQ | TLRY | |
|---|---|---|
Market Cap | $1.85B | $524.07M |
Sector | Technology | Health |
52-Week High | $27.32 | $21.00 |
52-Week Low | $15.04 | $4.23 |
Enterprise Value | $1.15B | $621.22M |
Signals from Pluang's Aura AI — not financial advice
MQ trades at $17.44, down slightly by 0.29% today. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Recent financials reveal revenue growth to $624.88M in 2025, but profitability remains weak with a net margin of -2.23%. The company's expansion into Europe with Expensify and a recent 4:1 reverse stock split are key developments. Analyst consensus is a 'Buy' with a $19.00 price target, indicating modest upside potential.
MQ presents a cautious opportunity with growth initiatives offset by profitability challenges. The stock's high P/E of 439 reflects investor optimism on future earnings, but thin margins and inconsistent quarterly results pose risks. Upside depends on successful execution of European expansion and sustained revenue growth, while downside risks include competitive pressures and failure to achieve profitability. Institutional sentiment is mixed, with 59% of analysts recommending 'Hold'.
TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.
The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.
Trailing returns across standard periods
Latest headlines on both assets
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →